German Pharma Balks As Second HTA Retrospective Assessment Includes Orphan Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
Germany’s senior reimbursement body, the G-BA, has announced it will assess a second wave of older drugs, despite a pending coalition agreement dropping this practice.